# A Dose Escalation Study of Bradanicline in Refractory Chronic Cough

> **NCT03622216** · PHASE2 · COMPLETED · sponsor: **Attenua, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Chronic Cough

## Interventions

- **DRUG:** Bradanicline
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03622216
- **Lead sponsor:** Attenua, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-05
- **Primary completion:** 2019-05-07
- **Final completion:** 2019-05-22
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03622216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03622216, "A Dose Escalation Study of Bradanicline in Refractory Chronic Cough". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03622216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*